Please assess the completion status of the following clinical trial:

Trial Title: Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Documented cancer of the pancreas who have failed (or are not candidates for) standard therapy~2. ECOG Performance Status of 0 to 1~3. Adequate organ function as defined by study-specified laboratory tests~4. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug~5. Signed informed consent form~6. Willing and able to comply with study procedures~Exclusion Criteria:~1. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions~2. Clinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0~3. Systemically active steroids~4. Another investigational product within 28 days prior to receiving study drug~5. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug~6. Infection with HIV, hepatitis B or C at screening~7. Pregnant or lactating~8. Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Ipilimumab Alone (Type: EXPERIMENTAL): Ipilimumab alone
- Arm 2: Ipilimumab + Pancreatic Cancer Vaccine (Type: EXPERIMENTAL): Ipilimumab + Pancreatic Cancer Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).